OPR - Delayed Quote • USD VRDN Sep 2024 20.000 put (VRDN240920P00020000) Follow 8.50 0.00 (0.00%) At close: April 23 at 3:56 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for VRDN240920P00020000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: VRDN Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress
